Table 1.
Receptor tyrosine kinase inhibitory activity at 50% of US Food and Drug Administration-approved TKIs in cell-free kinase assay (IC50)
| TKI | Tivozanib | Axitinib | Sunitinib | Pazopanib | Sorafenib |
|---|---|---|---|---|---|
| VEGFR-1 | 30 | ND | 21 | 7 | 9 |
| VEGFR-2 | 6.5 | 0.2 | 34 | 15 | 28 |
| VEGFR-3 | 15 | ND | 3 | 2 | 7 |
| PDGFR-B | 49 | 1.6 | 75 | 215 | 1129 |
| c-Kit | 78 | 1.7 | 40 | 48 | 1862 |
| FGFR-1 | 530 | ND | 437 | 80 | 64 |
Abbreviations: c-Kit, stem cell factor receptor; FGFR, fibroblast growth factor receptor; IC50, half-maximal inhibitory concentration; ND, not determined; PDGFR-B, platelet-derived growth factor receptor, beta; TKI, tyrosine kinase inhibitors; VEGFR, vascular endothelial growth factor.